Sight Sciences Announces First Quarter 2025 Revenues

Published on May 9, 2025
MENLO PARK, Calif.—Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, has announced financial results for the first quarter ended March 31, 2025, reporting first quarter 2025 total revenue of $17.5 million, a decrease of 9 percent compared with the same period in the prior year. This decline was primarily due to lower revenue from the company’s surgical glaucoma segment, which decreased 6 percent compared with the same period in the prior year, the company said. The expected decrease was primarily due to the new Medicare Local Coverage Determinations (LCDs) that restricted Medicare coverage for multiple Minimally Invasive Glaucoma Surgery (MIGS) procedures when performed at the same time as a cataract procedure, the company stated.
Continue reading on website
Other news

CIME 2025: Luke Lindsell, OD, MD, on bridging innovation and practical care in retinal disease

May 8, 2025
Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda light delivery system (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.

Prevent Blindness voices support for reintroduction of EDVI Act

May 9, 2025
The Early Detection of Vision Impairments for Children Act (EDVI), or HR 2527, would allow the federal government to award grants and cooperative agreements to eligible states and communities for children's vision care initiatives.